15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering LB Pharmaceuticals Inc Common Stock, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $34.00 to $78.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $46.29 sits 33% above the current $34.92. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.93 next quarter toward $-4.25 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to LB Pharmaceuticals Inc Common Stock.
As of Jul, 7 of 7 firms rate LBRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LBRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.93
Range $-1.04 – $-0.84 · 6 analysts · +52% YoY
Next period, 6 analysts expect LB Pharmaceuticals Inc Common Stock to earn $-0.93 a share (range $-1.04 – $-0.84), versus $-0.61 a year earlier. Full-year consensus is $-3.35, growing to $-4.25 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering LB Pharmaceuticals Inc Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LBRX.
#1
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$78.00+123.4% to target
Overall win rate
34%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$45.00+28.9% to target
Overall win rate
37%
+ Follow
#3
Paul Matteis
Stifel
Buy
$40.00+14.5% to target
Coverage
—
+ Follow
#4
AV
Adam Vogel
Craig-Hallum
Buy
$36.00+3.1% to target
Coverage
—
+ Follow
#5
Marc Goodman
Leerink Partners
Buy
$34.00-2.6% to target
Coverage
—
+ Follow
LBRX stock forecast FAQ
What is LBRX's average 12-month price target?+
The 7 analysts with a live target average $46.29 for LB Pharmaceuticals Inc Common Stock over the next 12 months, ranging from a $78.00 high to a $34.00 low.
Is LBRX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LBRX?+
The Street-high target is $78.00 (Piper Sandler), and the Street-low is $34.00 (Leerink Partners). The average of all 7 active targets is $46.29.
How many Wall Street analysts cover LBRX?+
7 analysts have an active rating on LB Pharmaceuticals Inc Common Stock, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering LBRX?+
Among analysts who currently cover LBRX, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #152). Their current call is Buy with a $78.00 target.
What is LB Pharmaceuticals Inc Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.93 per share (range $-1.04 – $-0.84) across 6 analysts. Full-year EPS is projected at $-3.35, rising to $-4.25 the following year.
How much revenue is LB Pharmaceuticals Inc Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading LBRX lately?+
As of Jul, 7 of 7 firms rate LBRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LBRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
BMO Capital
